Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 240

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 240
---
% to Kadimastem shareholders and 20% to NLS shareholders. The number of NLS Common Shares to be approved by the NLS shareholders will therefore include the necessary number of shares to achieve the approximate 80/20 ratio, along with a buffer of approximately 20%. The terms of, reasons for, and other aspects of the issuance of the Company’s ordinary shares as part of the Merger are described in detail in other sections in this prospectus/proxy statement. Please also see “ Preliminary Proxy Statement, Subject To Completion — Notice Of Extraordinary Meeting Of Shareholders To Be Held On , [2025] — 2. Ordinary Share Capital Increase with Contribution of the Kadimastem Shares to Implement the Merger” of this proxy statement/prospectus. To approve this Proposal2, a resolution passed by a Supermajority Vote is required. You may vote “FOR,” “AGAINST” or “ABSTAIN” on Proposal 2. A failure to vote, an abstention or a broker non -vote, if any, will have the same effect as a vote “AGAINST” Proposal 2. THE NLS BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE
“FOR” PROPOSAL 2 108 Approval of ORDINARY SHARE CAPITAL INCREASE BY ISSUING NLS PREFERRED SHARES (PROPOSAL 3) Under Swiss law, share capital may be increased through a resolution of the shareholders’ meeting (ordinary capital increase), which must be implemented by the NLS Board within six months to become effective. The amount by which the capital can be increased in an ordinary capital increase is unlimited, provided that sufficient contributions are made to cover the capital increase. The Company entered into the PIPE SPA with a certain accredited investor. Pursuant to the terms of the PIPE SPA, the Company has agreed to obtain shareholder approval to authorize and subsequently reserve a number of registered NLS Preferred Shares to enable the accredited investor to make additional investments of up to $10,000,000 in the Company. Accordingly, to fulfill the obligations under the PIPE SPA, at the extraordinary shareholders’ meeting, shareholders will be asked to approve the ordinary capital increase to create and issue the NLS Preferred Shares with a nominal value of CHF 0.03 each in accordance with the PIPE SPA. Please also see “ Preliminary Proxy Statement, Subject To Completion — Notice Of Extraordinary Meeting Of Shareholders To Be Held On , [2025] — 3. Ordinary Share Capital Increase by